Table 3.
irAEs without systemic corticosteroid administration versus no AE | irAEs with systemic corticosteroid administration versus no AE | irAEs with versus without corticosteroid administration | ||||
---|---|---|---|---|---|---|
OS | PFS | OS | PFS | OS | PFS | |
Original cohort, HR (95% CI) | ||||||
Naive cox | 0.45 (0.27–0.77) | 0.45 (0.28–0.73) | 0.33 (0.17–0.67) | 0.29 (0.14–0.57) | 0.52 (0.22–1.19) | 0.41 (0.17–0.99) |
Time-updated cox | 1.00 (0.59–1.67) | 0.94 (0.60–1.49) | 0.65 (0.31–1.37) | 0.60 (0.31–1.16) | 0.70 (0.36–1.39) | 0.51 (0.24–1.08) |
Emulated cohort, HR (95% CI) | ||||||
TTE | 1.01 (0.65–1.56) | 1.13 (0.73–1.75) | 0.80 (0.48–1.33) | 0.95 (0.62–1.46) | 0.80 (0.44–1.44) | 0.84 (0.51–1.41) |
All models were for adjusted for age, and sex, center, therapy line, ECOG (0/ ≥ 1), and localization of metastases (lymph node only disease/visceral metastases/missing) were added as strata. The TTE pooled weighted Cox model was additionally adjusted for study number as a natural cubic spline
OS, overall survival; PFS, progression-free survival; ORR, objective response rate; CR, complete response